Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake.

Health services research Outcome and Process Assessment, Health Care Quality Indicators, Health Care

Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
10 2022
Historique:
received: 29 06 2022
accepted: 18 07 2022
pubmed: 13 8 2022
medline: 15 9 2022
entrez: 12 8 2022
Statut: ppublish

Résumé

A clinical guideline is a document with the aim of guiding decisions based on evidence regarding diagnosis, management and treatment in specific areas of healthcare. Specific to rheumatic and musculoskeletal diseases (RMDs), adherence to clinical guidelines recommendations impacts the outcomes of people with these diseases. However, currently, the implementation of recommendations is less than optimal in rheumatology.The WHO has described the implementation of evidence-based recommendations as one of the greatest challenges facing the global health community and has identified the importance of scaling up these recommendations. But closing the evidence-to-practice gap is often complex, time-consuming and difficult. In this context, the implementation science offers a framework to overcome this scenario.This article describes the principles of implementation science to facilitate and optimise the implementation of clinical recommendations in RMDs. Embedding implementation science methods and techniques into recommendation development and daily practice can help maximise the likelihood that implementation is successful in improving the quality of healthcare and healthcare services.

Identifiants

pubmed: 35961760
pii: ard-2022-223016
doi: 10.1136/ard-2022-223016
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1344-1347

Subventions

Organisme : Department of Health
ID : NIHR 200259
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 20385
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR 200165
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 20380
Pays : United Kingdom
Organisme : Department of Health
ID : KMRF-2014-03-002
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 21019
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Estibaliz Loza (E)

Instituto de Salud Musculoesquelética (Inmusc), Madrid, Spain estibaliz.loza@inmusc.eu.

Loreto Carmona (L)

Instituto de Salud Musculoesquelética (Inmusc), Madrid, Spain.

Anthony Woolf (A)

Bone and Joint Research Group, Royal Cornwall Hospital, Truro, UK.

Bruno Fautrel (B)

Rheumatology, Pitie Salpetriere Hospital - Assistance Publique-Hopitaux de Paris, Paris, France.
INSERM UMRS 1136, Sorbonne University, Paris, France.

Delphine S Courvoisier (DS)

Division of Rheumatology, University of Geneva, Geneva, Switzerland.

Suzanne Verstappen (S)

Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Manchester Academic Health Science Centre, MRC Versus Arthritis Centre for Musculoskeletal Health and Work, University of Southampton, Southampton, UK.

Sella Aarrestad Provan (S)

Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.

Annelies Boonen (A)

Department of Internal Medicine, Division of Rheumatology, Maastrich University Medical Center+, Maastricht, Netherlands.
CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.

Thea Vliet Vlieland (T)

Orthopaedics, Rehabilitation and Physical Therapy, J11, Leiden University Medical Center, Leiden, Netherlands.

Francesca Marchiori (F)

EULAR PRP, Lupus Europe PAN, Rome, Italy.

Tiina Jasinski (T)

EULAR PRP, Eesti Reumaliit, Tallinn, Estonia.

Kristien Van der Elst (K)

Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium.

Mwidimi Ndosi (M)

School of Health and Social Wellbeing, University of the West of England, Bristol, UK.
Academic Rheumatology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Krysia Dziedzic (K)

Impact Accelerator Unit, School of Medicine, Keele University, Newcastle, UK.

Jose Miguel Carrasco (JM)

APLICA Investigación y Traslación Soc Coop Mad, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH